ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,059 | -22.3% | 29,703 | +0.5% | 0.01% | -14.3% |
| Q2 2023 | $1,363 | +16.4% | 29,553 | +1.2% | 0.01% | 0.0% |
| Q1 2023 | $1,171 | -12.8% | 29,193 | +0.7% | 0.01% | -12.5% |
| Q4 2022 | $1,343 | -99.9% | 28,983 | +1.3% | 0.01% | 0.0% |
| Q3 2022 | $1,185,000 | -29.7% | 28,613 | +1.3% | 0.01% | -27.3% |
| Q2 2022 | $1,685,000 | -3.3% | 28,243 | +17.7% | 0.01% | +10.0% |
| Q1 2022 | $1,742,000 | -12.2% | 23,989 | +1.6% | 0.01% | 0.0% |
| Q4 2021 | $1,985,000 | -5.2% | 23,609 | +1.7% | 0.01% | -16.7% |
| Q3 2021 | $2,093,000 | -2.2% | 23,209 | +3.5% | 0.01% | 0.0% |
| Q2 2021 | $2,139,000 | – | 22,430 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |